{
  "docId": "019de075-1597-7518-8ef8-7c76bda0fb5f",
  "docSlug": "a75249d5a456b06509b9b61a9aec1423",
  "documentTitle": "argenx SE | Results Presentation Deck | 15 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 15,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "disclaimer",
  "function": "other",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "This is a standard pharmaceutical product information slide.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1597-7518-8ef8-7c76bda0fb5f/7",
  "deckHref": "/decks/019de075-1597-7518-8ef8-7c76bda0fb5f",
  "deckJsonHref": "/decks/019de075-1597-7518-8ef8-7c76bda0fb5f.json",
  "deckAnchorHref": "/decks/019de075-1597-7518-8ef8-7c76bda0fb5f#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx. © 2023 argenx. All rights reserved",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33fc2a08-6525-4250-b471-fdb5026684a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.9,
        "w": 0.3,
        "x": 0.65,
        "y": 0.05
      },
      "kind": "image",
      "text": "VYVGART Hytrulo product branding",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "501c1f49-c0a5-4e63-aba4-32da60cd2851",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.55,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "list",
      "text": "WARNINGS AND PRECAUTIONS: Infections: delay administration to patients with active infection. Hypersensitivity reactions: angioedema, dyspnea, and rash have occurred.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93912601-6e8a-4570-96e4-54d06e3eaf79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.55,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "list",
      "text": "DOSING AND ADMINISTRATION: Administer by a healthcare professional only. Recommended dose is 1,008 mg / 11,200 units administered subcutaneously over approximately 30 to 90 seconds in cycles of once weekly injections for 4 weeks.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b93326cf-f547-4119-985c-eae39aba90ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "INDICATION STATEMENT: VYVGART Hytrulo is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c3ca785-8c5d-40ed-8a0e-2db0d551d183",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.55,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "ADVERSE REACTIONS: The most common adverse reactions (≥10%) in patients treated with intravenous VYVGART were respiratory tract infections, headaches, and urinary tract infection. Additional common adverse reactions with VYVGART Hytrulo are injection site reactions.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9279797-4470-4984-9117-f44f74ec1002",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3cf6cc8-1738-425d-8dd8-89fb5b338197",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}